Patent ID: 7098209

Claim:
A compound having a formula wherein R 0 , independently, is selected from the group consisting of halo and C 1-6 alkyl; R 1 is selected from the group consisting of hydro, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, haloC 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylC 1-3 alkyl, arylC 1-3 alkyl, C 1-3 alkylenearyl, and heteroarylC 1-3 alkyl; R 2 is selected from the group consisting of an optionally substituted monocyclic aromatic ring selected from the group consisting of benzene, thiophene, furan, and pyridine, and an optionally substituted bicyclic ring wherein the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; R 3 is selected from the group consisting of hydro and C 1-6 alkyl, or R 1 and R 3 together form a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring; R 4 is selected from the group consisting of C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 heterocycloalkyl, C 2-6 alkenyl, C 1-3 alkylenearyl, arylC 1-3 alkyl, heteroarylC 1-3 alkyl, C(═O)R a , aryl, heteroaryl, C(═O)OR a , C(═O)—NR a R b , C(═S)NR a R b , SO 2 R a , SO 2 OR a , SO 2 NR a R b , S(═O)R a , S(═O)NR a R b , C(═O)NR a C 1-4 alkyleneOR a , C(═O)NR a C 1-4 alkyleneHet, C(═O)C 1-4 alkylenearyl, C(═O)C 1-4 alkyleneheteroaryl, C 1-4 alkylenearyl substituted with one or more of SO 2 NR a R b , NR a R b , C(═O)OR a , NR a SO 2 CF 3 , CN, NO 2 , C(═O)R a , OR a , C 1-4 alkyleneNR a R b , and OC 1-4 alkyleneNR a R b , C 1-4 alkyleneHet, C 1-4 alkyleneC(═O) C 1-4 alkylenearyl, C 1-4 alkyleneC(═O)C 1-4 alkyleneheteroaryl, C 1-4 alkyleneC(═O)Het, C 1-4 alkyleneC(═O)NR a R b , C 1-4 alkyleneOR a , C 1-4 alkyleneNR a C (═O)R a , C 1-4 alkyleneOC 1-4 alkyleneOR a , C 1-4 alkyleneNR a R b , C 1-4 alkyleneC(═O)OR a , and C 1-4 alkyleneOC 1-4 alkyleneC(═O)OR a ; Het represents a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C 1-4 alkyl or C(═O)OR a ; R a is selected from the group consisting of hydro, C 1-6 alkyl, aryl, arylC 1-3 alkyl, C 1-3 alkylenearyl, heteroaryl, heteroarylC 1-3 alkyl, and C 1-3 alkyleneheteroaryl; R b is selected from the group consisting of hydro, C 1-6 alkyl, aryl, heteroaryl, arylC 1-3 alkyl, heteroarylC 1-3 alkyl, C 1-3 alkyleneN(R a ) 2 , C 1-3 alkylenearyl, C 1-3 alkyleneHet, haloC 1-3 alkyl, C 3-8 cycloalkyl, C 3-8 heterocycloalkyl, C 1-3 alkyleneheteroaryl, C 1-3 alkyleneC(═O)OR a , and C 1-3 alkyleneC 3-8 heterocycloalkyl; or R a and R b are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom; q is 0, 1, 2, 3, or 4; and pharmaceutically acceptable salts and hydrates thereof.